T Cell Antigen Gp39 Market, Global Outlook and Forecast 2022-2028
Report Code: KNJ1281538 No. of Pages: 72 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
This report contains market size and forecasts of T Cell Antigen Gp39 in global, including the following market information:
Global T Cell Antigen Gp39 Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global T Cell Antigen Gp39 Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five T Cell Antigen Gp39 companies in 2021 (%)
The global T Cell Antigen Gp39 market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
ECI-006 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of T Cell Antigen Gp39 include Biogen, Inc., Bristol-Myers Squibb Company, eTheRNA Immunotherapies NV, ImmuNext, Inc., Juno Therapeutics Inc., MedImmune, LLC, Targovax AS and XL-protein GmbH, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the T Cell Antigen Gp39 manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global T Cell Antigen Gp39 Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global T Cell Antigen Gp39 Market Segment Percentages, by Type, 2021 (%)
ECI-006
Hepatitis B Vaccine
INX-021
ISF-35
Others
Global T Cell Antigen Gp39 Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global T Cell Antigen Gp39 Market Segment Percentages, by Application, 2021 (%)
Graft Versus Host Disease
Breast Cancer
Bladder Cancer
Panceratic Cancer
Others
Global T Cell Antigen Gp39 Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global T Cell Antigen Gp39 Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies T Cell Antigen Gp39 revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies T Cell Antigen Gp39 revenues share in global market, 2021 (%)
Key companies T Cell Antigen Gp39 sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies T Cell Antigen Gp39 sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen, Inc.
Bristol-Myers Squibb Company
eTheRNA Immunotherapies NV
ImmuNext, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Targovax AS
XL-protein GmbH
1 Introduction to Research & Analysis Reports
1.1 T Cell Antigen Gp39 Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global T Cell Antigen Gp39 Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global T Cell Antigen Gp39 Overall Market Size
2.1 Global T Cell Antigen Gp39 Market Size: 2021 VS 2028
2.2 Global T Cell Antigen Gp39 Revenue, Prospects & Forecasts: 2017-2028
2.3 Global T Cell Antigen Gp39 Sales: 2017-2028
3 Company Landscape
3.1 Top T Cell Antigen Gp39 Players in Global Market
3.2 Top Global T Cell Antigen Gp39 Companies Ranked by Revenue
3.3 Global T Cell Antigen Gp39 Revenue by Companies
3.4 Global T Cell Antigen Gp39 Sales by Companies
3.5 Global T Cell Antigen Gp39 Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 T Cell Antigen Gp39 Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers T Cell Antigen Gp39 Product Type
3.8 Tier 1, Tier 2 and Tier 3 T Cell Antigen Gp39 Players in Global Market
3.8.1 List of Global Tier 1 T Cell Antigen Gp39 Companies
3.8.2 List of Global Tier 2 and Tier 3 T Cell Antigen Gp39 Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global T Cell Antigen Gp39 Market Size Markets, 2021 & 2028
4.1.2 ECI-006
4.1.3 Hepatitis B Vaccine
4.1.4 INX-021
4.1.5 ISF-35
4.1.6 Others
4.2 By Type - Global T Cell Antigen Gp39 Revenue & Forecasts
4.2.1 By Type - Global T Cell Antigen Gp39 Revenue, 2017-2022
4.2.2 By Type - Global T Cell Antigen Gp39 Revenue, 2023-2028
4.2.3 By Type - Global T Cell Antigen Gp39 Revenue Market Share, 2017-2028
4.3 By Type - Global T Cell Antigen Gp39 Sales & Forecasts
4.3.1 By Type - Global T Cell Antigen Gp39 Sales, 2017-2022
4.3.2 By Type - Global T Cell Antigen Gp39 Sales, 2023-2028
4.3.3 By Type - Global T Cell Antigen Gp39 Sales Market Share, 2017-2028
4.4 By Type - Global T Cell Antigen Gp39 Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global T Cell Antigen Gp39 Market Size, 2021 & 2028
5.1.2 Graft Versus Host Disease
5.1.3 Breast Cancer
5.1.4 Bladder Cancer
5.1.5 Panceratic Cancer
5.1.6 Others
5.2 By Application - Global T Cell Antigen Gp39 Revenue & Forecasts
5.2.1 By Application - Global T Cell Antigen Gp39 Revenue, 2017-2022
5.2.2 By Application - Global T Cell Antigen Gp39 Revenue, 2023-2028
5.2.3 By Application - Global T Cell Antigen Gp39 Revenue Market Share, 2017-2028
5.3 By Application - Global T Cell Antigen Gp39 Sales & Forecasts
5.3.1 By Application - Global T Cell Antigen Gp39 Sales, 2017-2022
5.3.2 By Application - Global T Cell Antigen Gp39 Sales, 2023-2028
5.3.3 By Application - Global T Cell Antigen Gp39 Sales Market Share, 2017-2028
5.4 By Application - Global T Cell Antigen Gp39 Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global T Cell Antigen Gp39 Market Size, 2021 & 2028
6.2 By Region - Global T Cell Antigen Gp39 Revenue & Forecasts
6.2.1 By Region - Global T Cell Antigen Gp39 Revenue, 2017-2022
6.2.2 By Region - Global T Cell Antigen Gp39 Revenue, 2023-2028
6.2.3 By Region - Global T Cell Antigen Gp39 Revenue Market Share, 2017-2028
6.3 By Region - Global T Cell Antigen Gp39 Sales & Forecasts
6.3.1 By Region - Global T Cell Antigen Gp39 Sales, 2017-2022
6.3.2 By Region - Global T Cell Antigen Gp39 Sales, 2023-2028
6.3.3 By Region - Global T Cell Antigen Gp39 Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America T Cell Antigen Gp39 Revenue, 2017-2028
6.4.2 By Country - North America T Cell Antigen Gp39 Sales, 2017-2028
6.4.3 US T Cell Antigen Gp39 Market Size, 2017-2028
6.4.4 Canada T Cell Antigen Gp39 Market Size, 2017-2028
6.4.5 Mexico T Cell Antigen Gp39 Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe T Cell Antigen Gp39 Revenue, 2017-2028
6.5.2 By Country - Europe T Cell Antigen Gp39 Sales, 2017-2028
6.5.3 Germany T Cell Antigen Gp39 Market Size, 2017-2028
6.5.4 France T Cell Antigen Gp39 Market Size, 2017-2028
6.5.5 U.K. T Cell Antigen Gp39 Market Size, 2017-2028
6.5.6 Italy T Cell Antigen Gp39 Market Size, 2017-2028
6.5.7 Russia T Cell Antigen Gp39 Market Size, 2017-2028
6.5.8 Nordic Countries T Cell Antigen Gp39 Market Size, 2017-2028
6.5.9 Benelux T Cell Antigen Gp39 Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia T Cell Antigen Gp39 Revenue, 2017-2028
6.6.2 By Region - Asia T Cell Antigen Gp39 Sales, 2017-2028
6.6.3 China T Cell Antigen Gp39 Market Size, 2017-2028
6.6.4 Japan T Cell Antigen Gp39 Market Size, 2017-2028
6.6.5 South Korea T Cell Antigen Gp39 Market Size, 2017-2028
6.6.6 Southeast Asia T Cell Antigen Gp39 Market Size, 2017-2028
6.6.7 India T Cell Antigen Gp39 Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America T Cell Antigen Gp39 Revenue, 2017-2028
6.7.2 By Country - South America T Cell Antigen Gp39 Sales, 2017-2028
6.7.3 Brazil T Cell Antigen Gp39 Market Size, 2017-2028
6.7.4 Argentina T Cell Antigen Gp39 Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa T Cell Antigen Gp39 Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa T Cell Antigen Gp39 Sales, 2017-2028
6.8.3 Turkey T Cell Antigen Gp39 Market Size, 2017-2028
6.8.4 Israel T Cell Antigen Gp39 Market Size, 2017-2028
6.8.5 Saudi Arabia T Cell Antigen Gp39 Market Size, 2017-2028
6.8.6 UAE T Cell Antigen Gp39 Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Biogen, Inc.
7.1.1 Biogen, Inc. Corporate Summary
7.1.2 Biogen, Inc. Business Overview
7.1.3 Biogen, Inc. T Cell Antigen Gp39 Major Product Offerings
7.1.4 Biogen, Inc. T Cell Antigen Gp39 Sales and Revenue in Global (2017-2022)
7.1.5 Biogen, Inc. Key News
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Corporate Summary
7.2.2 Bristol-Myers Squibb Company Business Overview
7.2.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Major Product Offerings
7.2.4 Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales and Revenue in Global (2017-2022)
7.2.5 Bristol-Myers Squibb Company Key News
7.3 eTheRNA Immunotherapies NV
7.3.1 eTheRNA Immunotherapies NV Corporate Summary
7.3.2 eTheRNA Immunotherapies NV Business Overview
7.3.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Major Product Offerings
7.3.4 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales and Revenue in Global (2017-2022)
7.3.5 eTheRNA Immunotherapies NV Key News
7.4 ImmuNext, Inc.
7.4.1 ImmuNext, Inc. Corporate Summary
7.4.2 ImmuNext, Inc. Business Overview
7.4.3 ImmuNext, Inc. T Cell Antigen Gp39 Major Product Offerings
7.4.4 ImmuNext, Inc. T Cell Antigen Gp39 Sales and Revenue in Global (2017-2022)
7.4.5 ImmuNext, Inc. Key News
7.5 Juno Therapeutics Inc.
7.5.1 Juno Therapeutics Inc. Corporate Summary
7.5.2 Juno Therapeutics Inc. Business Overview
7.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Major Product Offerings
7.5.4 Juno Therapeutics Inc. T Cell Antigen Gp39 Sales and Revenue in Global (2017-2022)
7.5.5 Juno Therapeutics Inc. Key News
7.6 MedImmune, LLC
7.6.1 MedImmune, LLC Corporate Summary
7.6.2 MedImmune, LLC Business Overview
7.6.3 MedImmune, LLC T Cell Antigen Gp39 Major Product Offerings
7.6.4 MedImmune, LLC T Cell Antigen Gp39 Sales and Revenue in Global (2017-2022)
7.6.5 MedImmune, LLC Key News
7.7 Targovax AS
7.7.1 Targovax AS Corporate Summary
7.7.2 Targovax AS Business Overview
7.7.3 Targovax AS T Cell Antigen Gp39 Major Product Offerings
7.7.4 Targovax AS T Cell Antigen Gp39 Sales and Revenue in Global (2017-2022)
7.7.5 Targovax AS Key News
7.8 XL-protein GmbH
7.8.1 XL-protein GmbH Corporate Summary
7.8.2 XL-protein GmbH Business Overview
7.8.3 XL-protein GmbH T Cell Antigen Gp39 Major Product Offerings
7.8.4 XL-protein GmbH T Cell Antigen Gp39 Sales and Revenue in Global (2017-2022)
7.8.5 XL-protein GmbH Key News
8 Global T Cell Antigen Gp39 Production Capacity, Analysis
8.1 Global T Cell Antigen Gp39 Production Capacity, 2017-2028
8.2 T Cell Antigen Gp39 Production Capacity of Key Manufacturers in Global Market
8.3 Global T Cell Antigen Gp39 Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 T Cell Antigen Gp39 Supply Chain Analysis
10.1 T Cell Antigen Gp39 Industry Value Chain
10.2 T Cell Antigen Gp39 Upstream Market
10.3 T Cell Antigen Gp39 Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 T Cell Antigen Gp39 Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com